The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
The Clinical Management of Sarcoidosis A 50-Year Experience at the Johns Hopkins Hospital
Abstract
Sarcoidosis is an enigmatic disease with extremely variable manifestations in pattern, severity and course. Since Longcope and Freiman's descriptive monograph in 1952 (50) summarizing the clinical findings of the first half of this century, new dimensions of assessing the disease and treatment have been added. The impact of corticosteroids is central. The present review extends the studies to the second half of this century. Earlier diagnosis is facilitated and treatment often reverses many of the disease manifestations and improves the quality and extent of life for the patient. The management issues and guidelines outlined in this paper for both intrathoracic and extrathoracic disease are based on several longitudinal studies of the sarcoidosis patients summarized here, and 50 years of clinical experience by the senior author (CJJ) at Johns Hopkins Hospital, a tertiary referral center with an active Sarcoid Clinic. Case reports are presented in the appendix. It is clear that corticosteroids are the most effective therapeutic agent for sarcoidosis, usually with impressive and prompt response. This represents the dramatic difference in this disease after 1950. No more specific or effective immunosuppressive or antiinflammatory agents have been identified. Undesirable side effects are minimal if excessive doses are avoided. The effectiveness of "steroid-sparing agents" such as methotrexate is uncertain. Although irreversible tissue damage from the disease may limit the effectiveness of treatment, benefits of corticosteroids greatly exceed the negative side effects. Since spontaneous remissions without treatment do occur, a period of observation of 2 years are more is warranted if the patient is relatively asymptomatic. Gradual radiographic progression for 2 or more years, even without major symptoms or reduction in pulmonary function, indicates the need for a trial of corticosteroid treatment, especially in white patients where symptoms may lag behind the radiographic changes. Relapses as treatment is withdrawn are frequent, especially in African-American patients, who tend to have more severe and more prolonged disease than white patients. A minimum of 1 year of treatment is recommended unless no improvement is noted after 3 months. Continued low-dose prednisone at daily doses of 10-15 mg is helpful in preventing relapses and further progression of disease. Periodic attempts at tapering are justified. Repeated relapses may indicate the need for life-long treatment. When irreversible changes are present, especially in the presence of chronic fibrotic disease, changing goals of treatment to provide optimal supportive care may represent better management than having unrealistic expectations from increased corticosteroid dosage or the addition of other potentially toxic immunosuppressive agents. Many agents related to sarcoidosis require further research. The most important question facing sarcoid researchers today is etiology. It is difficult to design specific therapy when the fundamental causes and disease mechanisms are not established. Rather than being a single disease with a single cause, it is possible that a number of genetic factors and environmental or infectious agents may result in an immune response that is manifested as sarcoidosis. Understanding basic causal mechanisms may help explain the varied disease manifestations and aid in designing curative treatments. Such etiologic questions should be explored from both a basic science and an epidemiologic approach. Therapeutic trials of new drugs such as pentoxyfylline and possibly thalidomide are needed to address their potential as well as limitations of steroid therapy. Finally, for patients who have progressed to organ failure, the problems of sarcoid recurrence in transplanted tissue, increased allograft rejection, and long-term prognosis of solid organ transplants have yet to be resolved. (ABSTRACT TRUNCATED)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Newman, L. S., Rose, C. S., & Maier, L. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361706 · Cited by 1,235
Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.
Silverman, K. J., Hutchins, G. M., & Bulkley, B. H. (1978) · Circulation · doi:10.1161/01.cir.58.6.1204 · Cited by 984
Mayock, R. L., Bertrand, P., Morrison, C. E., & Scott, J. H. (1963) · The American Journal of Medicine · doi:10.1016/0002-9343(63)90165-7 · Cited by 800
Li-ping, E., & Hospita, P. (2008) · Zhonghua linchuang mianyi he biantai fanying zazhi · Cited by 719
Sarcoidosis and Its Neurological Manifestations
Stern, B. J., Krumholz, A., Johns, C., Scott, P., & Nissim, J. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060080095022 · Cited by 714
Self-citationLONGCOPE, W. T., & PREIMAN, D. G. (1952) · Medicine · doi:10.1097/00005792-195202000-00001 · Cited by 710
Course and prognosis of sarcoidosis around the world
Siltzbach, L. E., James, D. G., Neville, E., Turiaf, J., Battesti, J. P., Sharma, O. P., Hosoda, Y., Mikami, R., & Odaka, M. (1974) · The American Journal of Medicine · doi:10.1016/0002-9343(74)90160-0 · Cited by 526
Ocular Involvement in Chronic Sarcoidosis
Jabs, D. A., & Johns, C. J. (1986) · American Journal of Ophthalmology · doi:10.1016/0002-9394(86)90001-2 · Cited by 391
Self-citationBritish Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.
Gibson, G. J., Prescott, R. J., Muers, M. F., Middleton, W. G., Mitchell, D. N., Connolly, C. K., & Harrison, B. D. (1996) · Thorax · doi:10.1136/thx.51.3.238 · Cited by 348
Gottlieb, J. E., Israel, H. L., Steiner, R. M., Triolo, J., & Patrick, H. (1997) · Chest · doi:10.1378/chest.111.3.623 · Cited by 310
Cited by
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Cooper, L. T., Baughman, K. L., Feldman, A. M., Frustaci, A., Jessup, M., Kuhl, U., Levine, G. N., Narula, J., Starling, R. C., Towbin, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.186093 · Cited by 1,030
The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease
Cooper, L. T., Baughman, K. L., Feldman, A. M., Frustaci, A., Jessup, M., Kuhl, U., Levine, G. N., Narula, J., Starling, R. C., Towbin, J., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.008 · Cited by 672
Baughman, R. P., Lower, E. E., & du Bois, R. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12888-7 · Cited by 657
Smedema, J.-P., Snoep, G., van Kroonenburgh, M. P. G., van Geuns, R.-J., Dassen, W. R. M., Gorgels, A. P. M., & Crijns, H. J. G. M. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.047 · Cited by 566
Metadata
- Authors
- Johns, C. J., & Michele, T. M.
- Venue
- Medicine
- Published
- 1999-03
- Volume
- 78
- Issue
- 2
- Pages
- 65-111
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2313141792
- Cited by
- 310
- References
- 27
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical Management of Sarcoidosis A 50-Year Experience at the Johns Hopkins Hospital. https://app.cochat.ai/papers/10.1097/00005792-199903000-00001
- The paper
- Johns, C. J., & Michele, T. M. (1999). The Clinical Management of Sarcoidosis A 50-Year Experience at the Johns Hopkins Hospital. Medicine. https://doi.org/10.1097/00005792-199903000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.